Explore
Validate
Learn
Flow cytometryAntibody data
- Antibody Data
- Antigen structure
- References [7]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- ABIN488147 - Provider product page
- Provider
- antibodies-online
- Product name
- anti-Mast/stem Cell Growth Factor Receptor (KIT) antibody (FITC)
- Antibody type
- Monoclonal
- Antigen
- MOLM-1 cells. Remarks: Hybridoma was established by fusion of mouse myeloma cell Sp2/0 with Balb/c mouse splenocyte.
- Description
- Protein A Agarose Chromatography of hybridoma supernatant
- Reactivity
- Human
- Host
- Mouse
- Conjugate
- Green dye
- Isotype
- IgG
- Antibody clone number
- 104D2
- Vial size
- 50 μg
- Concentration
- 0.5 mg/mL
- Storage
- Store undiluted at 2-8°C for one month or (in aliquots) at -20°C for longer.
- Handling
- Avoid repeated freezing and thawing.
Submitted references Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis.
Secondary amyloidosis and eosinophilia in a patient with uterine leiomyosarcoma.
Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation.
Tumor necrosis factor-alpha-converting enzyme controls surface expression of c-Kit and survival of embryonic stem cell-derived mast cells.
c-kit is not expressed in Hodgkin disease and anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma.
Aberrant activation of c-kit protects colon carcinoma cells against apoptosis and enhances their invasive potential.
The role of HIV-related chemokine receptors and chemokines in human erythropoiesis in vitro.
Shah NP, Lee FY, Luo R, Jiang Y, Donker M, Akin C
Blood 2006 Jul 1;108(1):286-91
Blood 2006 Jul 1;108(1):286-91
Secondary amyloidosis and eosinophilia in a patient with uterine leiomyosarcoma.
Onishi S, Hojo N, Sakai I, Matsumoto T, Watanabe A, Miyazaki T, Ito MR, Nose M, Fujita S
Japanese journal of clinical oncology 2005 Oct;35(10):617-21
Japanese journal of clinical oncology 2005 Oct;35(10):617-21
Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation.
Gotlib J, Berubé C, Growney JD, Chen CC, George TI, Williams C, Kajiguchi T, Ruan J, Lilleberg SL, Durocher JA, Lichy JH, Wang Y, Cohen PS, Arber DA, Heinrich MC, Neckers L, Galli SJ, Gilliland DG, Coutré SE
Blood 2005 Oct 15;106(8):2865-70
Blood 2005 Oct 15;106(8):2865-70
Tumor necrosis factor-alpha-converting enzyme controls surface expression of c-Kit and survival of embryonic stem cell-derived mast cells.
Cruz AC, Frank BT, Edwards ST, Dazin PF, Peschon JJ, Fang KC
The Journal of biological chemistry 2004 Feb 13;279(7):5612-20
The Journal of biological chemistry 2004 Feb 13;279(7):5612-20
c-kit is not expressed in Hodgkin disease and anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma.
Rassidakis GZ, Georgakis GV, Younes A, Medeiros LJ
Blood 2003 Dec 15;102(13):4619-20
Blood 2003 Dec 15;102(13):4619-20
Aberrant activation of c-kit protects colon carcinoma cells against apoptosis and enhances their invasive potential.
Bellone G, Carbone A, Sibona N, Bosco O, Tibaudi D, Smirne C, Martone T, Gramigni C, Camandona M, Emanuelli G, Rodeck U
Cancer research 2001 Mar 1;61(5):2200-6
Cancer research 2001 Mar 1;61(5):2200-6
The role of HIV-related chemokine receptors and chemokines in human erythropoiesis in vitro.
Majka M, Ratajczak J, Lee B, Honczarenko M, Douglas R, Kowalska MA, Silberstein L, Gewirtz AM, Ratajczak MZ
Stem cells (Dayton, Ohio) 2000;18(2):128-38
Stem cells (Dayton, Ohio) 2000;18(2):128-38
No comments: Submit comment
No validations: Submit validation data